128 related articles for article (PubMed ID: 30504384)
1. Neutrophil Gelatinase-associated Lipocalin as a Theragnostic Marker in Perihilar Cholangiocarcinoma.
Nair A; Ingram N; Verghese ET; Wijetunga I; Markham AF; Wyatt J; Prasad KR; Coletta PL
Anticancer Res; 2018 Dec; 38(12):6737-6744. PubMed ID: 30504384
[TBL] [Abstract][Full Text] [Related]
2. Expression of integrin ανβ6 differentiates perihilar cholangiocarcinoma (PHC) from benign disease mimicking PHC.
Franken LC; Vuijk FA; Soer EC; Roos E; Erdmann JI; Hooijer GKJ; Vahrmeijer AL; Gambhir SS; van Gulik TM; Sarasqueta AF; Verheij J; Swijnenburg RJ
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):628-634. PubMed ID: 33069505
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the Clinical Applicability of the European Staging System for Perihilar Cholangiocarcinoma.
Ismael HN; Loyer E; Kaur H; Conrad C; Vauthey JN; Aloia T
J Gastrointest Surg; 2016 Apr; 20(4):741-7. PubMed ID: 26801328
[TBL] [Abstract][Full Text] [Related]
4. Autophagy activity in cholangiocarcinoma is associated with anatomical localization of the tumor.
Lendvai G; Szekerczés T; Illyés I; Csengeri M; Schlachter K; Szabó E; Lotz G; Kiss A; Borka K; Schaff Z
PLoS One; 2021; 16(6):e0253065. PubMed ID: 34129628
[TBL] [Abstract][Full Text] [Related]
5. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas.
Akita M; Fujikura K; Ajiki T; Fukumoto T; Otani K; Azuma T; Itoh T; Ku Y; Zen Y
Mod Pathol; 2017 Jul; 30(7):986-997. PubMed ID: 28338651
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of TIE2-expressing monocytes in hilar cholangiocarcinoma.
Atanasov G; Hau HM; Dietel C; Benzing C; Krenzien F; Brandl A; Englisch JP; Wiltberger G; Schierle K; Robson SC; Reutzel-Selke A; Jonas S; Pascher A; Pratschke J; Schmelzle M
J Surg Oncol; 2016 Jul; 114(1):91-8. PubMed ID: 27111031
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Inflammation-based Prognostic Scores in Patients With Biliary Tract Cancer After Surgical Resection.
Utsumi M; Kitada K; Tokunaga N; Yoshida Y; Narusaka T; Hamano R; Miyasou H; Tsunemitsu Y; Otsuka S; Inagaki M
Anticancer Res; 2021 Apr; 41(4):2147-2155. PubMed ID: 33813426
[TBL] [Abstract][Full Text] [Related]
9. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
10. IgG4-Associated Cholangitis in Patients Resected for Presumed Perihilar Cholangiocarcinoma: a 30-Year Tertiary Care Experience.
Roos E; Hubers LM; Coelen RJS; Doorenspleet ME; de Vries N; Verheij J; Beuers U; van Gulik TM
Am J Gastroenterol; 2018 May; 113(5):765-772. PubMed ID: 29549357
[TBL] [Abstract][Full Text] [Related]
11. Cystic duct carcinoma and type I/II perihilar cholangiocarcinoma: Clinicopathological features and a new differential diagnosis model.
Nan L; Wang C; Wang J; Xu S; Bo X; Liu H; Wang Y
Eur J Surg Oncol; 2023 Dec; 49(12):107099. PubMed ID: 37826965
[No Abstract] [Full Text] [Related]
12. Prognostic Value of Hepatocyte Growth Factor Receptor Expression in Patients with Perihilar Cholangiocarcinoma.
Watanabe H; Yokoyama Y; Kokuryo T; Ebata T; Igami T; Sugawara G; Mizuno T; Shimoyama Y; Nagino M
Ann Surg Oncol; 2015 Jul; 22(7):2235-42. PubMed ID: 25586241
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.
Wang Y; Wan M; Zhou Q; Wang H; Wang Z; Zhong X; Zhang L; Tai S; Cui Y
PLoS One; 2015; 10(10):e0141165. PubMed ID: 26485275
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Prdx1 in hilar cholangiocarcinoma: a predictor for recurrence and prognosis.
Zhou J; Shen W; He X; Qian J; Liu S; Yu G
Int J Clin Exp Pathol; 2015; 8(9):9863-74. PubMed ID: 26617696
[TBL] [Abstract][Full Text] [Related]
15. SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma.
Yu Y; Chen Y; Ma J; Yu X; Yu G; Li Z
Tumour Biol; 2016 Mar; 37(3):4159-67. PubMed ID: 26490986
[TBL] [Abstract][Full Text] [Related]
16. Perihilar Cholangiocarcinoma.
Nath MC; Torbenson MS; Erickson LA
Mayo Clin Proc; 2018 Mar; 93(3):397-398. PubMed ID: 29502573
[No Abstract] [Full Text] [Related]
17. Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes.
Srisomsap C; Sawangareetrakul P; Subhasitanont P; Chokchaichamnankit D; Chiablaem K; Bhudhisawasdi V; Wongkham S; Svasti J
J Biomed Biotechnol; 2010; 2010():437143. PubMed ID: 20069059
[TBL] [Abstract][Full Text] [Related]
18. PTPN3 suppresses the proliferation and correlates with favorable prognosis of perihilar cholangiocarcinoma by inhibiting AKT phosphorylation.
Sun R; Chen T; Li M; Liu Z; Qiu B; Li Z; Xu Y; Pan C; Zhang Z
Biomed Pharmacother; 2020 Jan; 121():109583. PubMed ID: 31706106
[TBL] [Abstract][Full Text] [Related]
19. Expression of Smad7 in cholangiocarcinoma: prognostic significance and implications for tumor metastasis.
Huang Q; Liu L; Liu CH; Shao F; Xie F; Zhang CH; Hu SY
Asian Pac J Cancer Prev; 2012; 13(10):5161-5. PubMed ID: 23244128
[TBL] [Abstract][Full Text] [Related]
20. Expressions of neutrophil gelatinase-associated lipocalin in gastric cancer: a potential biomarker for prognosis and an ancillary diagnostic test.
Wang HJ; He XJ; Ma YY; Jiang XT; Xia YJ; Ye ZY; Zhao ZS; Tao HQ
Anat Rec (Hoboken); 2010 Nov; 293(11):1855-63. PubMed ID: 20730863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
